Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

Global Breakthrough: FGC2.3 Feline Vocalization Project Nears Record Reads — Over 14,000 Scientists Engage With Cat-Human Translation Research

MIAMI, FL — The FGC2.3: Feline Vocalization Classification and Cat Translation Project, authored by Dr. Vladislav Reznikov, has crossed a critical scientific milestone — surpassing 14,000 reads on ResearchGate and rapidly climbing toward record-setting levels in the field of animal communication and artificial intelligence. This pioneering work aims to develop the world’s first scientifically grounded…

Tariff-Free Relocation to the US

Tariff-Free Relocation to the US

EU, China, and more are now in the crosshairs. How’s next? It’s time to act. The Trump administration has announced sweeping tariff hikes, as high as 50%, on imports from the European Union, China, and other major markets. Affected industries? Pharmaceuticals, Biotech, Medical Devices, IVD, and Food Supplements — core sectors now facing crippling costs,…

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

Global Distribution of the NRAs Maturity Levels as of the WHO Global Benchmarking Tool and the ICH data

This study presents the GDP Matrix by Dr. Vlad Reznikov, a bubble chart designed to clarify the complex relationships between GDP, PPP, and population data by categorizing countries into four quadrants—ROCKSTARS, HONEYBEES, MAVERICKS, and UNDERDOGS depending on National Regulatory Authorities (NRAs) Maturity Level (ML) of the regulatory affairs requirements for healthcare products. Find more details…

“Living Pharmacy” Implant Extends Lifespan of Drug-producing Cells Significantly

“Living Pharmacy” Implant Extends Lifespan of Drug-producing Cells Significantly

Cells that have been genetically engineered to produce drugs are a promising way to deliver medicines inside the human body, but keeping those cells alive is challenging. A new bioelectronic implant can now support populations of three different drug-producing cells for more than a month. The researchers behind the result say it’s a step toward “living pharmacies” that can deliver a range of drugs on demand.

But another promising avenue involves using genetic engineering to turn cells into living drug factories that can pump out a class of medicines known as “biologics”—drugs derived from living organisms. The U.S. Food and Drug Administration has approved biologics targeting a wide range of conditions, including various cancers, autoimmune diseases like arthritis and psoriasis, and chronic conditions like asthma and Crohn’s disease.

For the approach to work, the cells need to stay alive long enough in the host’s body to produce the correct dose of the medicine. One of the biggest barriers is ensuring that the cells receive enough oxygen to thrive. The multi-institution team behind the latest development has created a bioelectronic implant the size of a thumb drive that houses drug-producing cells and also uses electrochemical reactions to provide a reliable supply of oxygen to them.

Bioelectronic Implant Extends Cell Survival

In a recent paper in Device, the team showed the implant could sustain three different strains of engineered cells for 31 days when implanted in rats, providing steady production of multiple drugs. While the implant remains a proof-of-concept, the long term goal is to create a device that can control the timing and dosage of multiple therapies over extended periods, says Jonathan Rivnay, a professor of biomedical engineering at Northwestern University.

“Imagine a device that’s a few millimeters that you can put under your skin, and it can serve this purpose of a multi-therapeutic living pharmacy that can last for months to years,” Rivnay says. “That would be game changing. I think we have a long way to go, but the kind of advances that we’re writing about in this article are laying the foundation for what that might look like.”

Access to oxygen is the main limitation for this kind of cell therapy, says Omid Vseih, a professor of bioengineering at Rice University. The area directly under the skin, which is an attractive target for implants because it can be accessed using minimally invasive procedures, tends to be particularly poorly oxygenated.

One potential solution are electrochemical approaches that convert water into oxygen and hydrogen. But these approaches have primarily been developed for industrial applications that don’t translate well to the constraints of operating inside the body or using its water. Specifically, they have high power requirements and potentially produce toxic byproducts like chlorine and hydrogen peroxide.

Previous research from the same researchers demonstrated a device that used a thin film of iridium oxide as a catalyst to generate oxygen, which enabled it to run at voltages between 1.6 and 1.9 volts (lower than other electrochemical reactions), and minimized the creation of harmful byproducts. But the device still required an external power source.

HOBIT Wireless Oxygenation Implant System

Building on that work, the researchers have now built a device they call HOBIT (Hybrid Oxygenation Bioelectronics system for Implanted Therapy) that integrates an oxygenator, a chamber for housing cells, a wireless communication system to control oxygen production and transmit data, and an internal battery into a hermetically sealed implant just 4.5 centimeters long.

“I think the power is in the fully implantable nature of this platform,” says Chris Wright, a Ph.D. student at Rice. “You don’t need external power, you don’t need external devices that connect to it. That’s a big differentiator.”

The cells are encapsulated in permeable gel capsules that allow nutrients and drugs to pass through, but prevents cells from escaping or being attacked by the body’s immune system.

The device is able to house drug-producing cells at a density as high as 60 million per milliliter. That density allowed the researchers to load three different engineered cell strains designed to produce an anti-HIV antibody, a hormone that regulates metabolism, and a peptide similar to the weight loss drug GLP-1.

These drugs all last different amounts of time in the body, but by balancing the ratios of the cells and controlling the oxygen supply the researchers were able to maintain steady production of each drug therapy for 31 days. By the end of the trial, 64.6 percent of cells were still viable, compared to just 19.2 percent in a control device without an oxygenator.

This ability to produce several drugs at reliable levels over extended periods could significantly reduce the burden of administering complex multi-therapy treatment regimes, says Vseih. The team is already working to apply the technology as part of a project funded by the Advanced Research Projects Agency for Health (ARPA-H) called THOR (Targeted Hybrid Oncotherapeutic Regulation), which will produce multiple cancer-fighting immunotherapies with different half lives in the abdomen.

Rivnay says that they hope to one day augment the device with sensors that can detect various biomarkers, as well as ways to control drug production using optogenetics and electrogenetics—methods for altering the genetic activity of cells using flashes of light or pulses of electricity, respectively. “All of those things layer onto a more complex living-pharmacy-type system, building that longer term vision of not only controlling dose but controlling exactly when you supply a dose,” he says.

One outstanding challenge will be getting approval from the FDA—the agency has yet to sanction a biohybrid device that combines both living and non-living components. But Rivnay remains confident that with the right approach they can win over regulators.

“It’s just a matter of showing that it’s safe and showing that it’s effective,” he says. “That’s why we have to start relatively simple and not throw all the bells and whistles at it straight away.”

AI Tool Developed by Young Professionals Identifies Mental Health Issues

AI Tool Developed by Young Professionals Identifies Mental Health Issues

Abhishek Appaji has committed his career to bringing lifesaving technology to underresourced communities. The IEEE senior member weaves together artificial intelligence, biomedical engineering, deep learning, and neuroscience to make doctors’ jobs easier and to improve patient outcomes.

“The intersection of these fields is where the most impactful breakthroughs in diagnostic precision occur,” says Appaji, an associate professor of medical electronics engineering at the B.M.S. College of Engineering, in Bengaluru, India.

Abhishek Appaji

Employer

B.M.S. College of Engineering, in Bengaluru, India

Job title

Associate professor of medical electronics engineering

Member grade

IEEE senior member

Alma maters

B.M.S. College of Engineering; University of Visvesvaraya, in Bengaluru; Maastricht University, in the Netherlands

Many of his inventions have been deployed in remote areas of India, providing physicians with quality diagnostic tools, including an AI-powered machine that can scan retinas to detect medical conditions and a smart bed that continuously monitors a patient’s vital signs.

An active volunteer with the IEEE Young Professionals Bangalore Section, he has launched professional networking events, technology workshops, a mentorship program, and other initiatives.

For his “contributions to accessible AI-driven health care solutions and leadership in empowering young professionals,” Appaji is the recipient of this year’s IEEE Theodore W. Hissey Outstanding Young Professional Award. The honor is sponsored by the IEEE Photonics and Power & Energy societies as well as IEEE Young Professionals. The award is scheduled to be presented this month during the IEEE Honors Ceremony in New York City.

“This award represents a significant milestone in my career,” Appaji says. “It validates my core belief that our success as engineers is not solely measured by research outcomes or publications but by the tangible impact we have on lives through accessible technology and the quality of the next generation of leaders we empower.”

Developing a blood glucose measurement device

After earning a bachelor’s degree in engineering from B.M.S. in 2010, he joined the school as a lecturer in its medical electronics engineering department. At the same time, he pursued master’s degrees in bioinformatics at the University Visvesvarya College of Engineering, also in Bengaluru. He graduated in 2013 and continued to teach at B.M.S.C.E.

Four years later, Appaji signed up for the MIT Global Entrepreneurship Bootcamp, a two-week intensive hybrid program that includes webinars, online courses, and a five-day stay at MIT. It’s designed to give teams of aspiring entrepreneurs, innovators, and early-stage founders the structured mindset, tools, and frameworks they need to succeed.

Appaji says he discovered the program while researching opportunities in innovation.

“I had the technical expertise, but I needed a structured framework to transition my research from the laboratory to the market,” he says.

During the MIT boot camp, he and a team of four other participants were tasked with approaching a complex health care challenge. They developed a noninvasive blood glucose measurement device to manage gestational diabetes—a condition that causes high blood sugar and insulin resistance during pregnancy. When the program ended, Appaji and two of his Australia-based teammates continued their collaboration by founding Glucotek in Brisbane, Australia.

Inspired to continue his research in health care technology, Appaji pursued a doctorate in mental health and neurosciences at Maastricht University, in the Netherlands.

His thesis focused on computational methods to identify retinal vascular patterns.

“The patterns we analyze—including the curvature of the vessels, the angles at which they branch out, and their dimensions—reveal the health of the microvascular system,” he says. “With conditions like schizophrenia and bipolar disorder, microvascular changes mirror neurovascular changes in the brain.”

“My journey has shown me that IEEE is much more than a professional society; it is a global platform that allows me to collaborate with a diverse network of experts to solve local humanitarian challenges.”

Examining and measuring the retinal vascular system offers physicians a noninvasive way to examine neural changes, which can be biomarkers for psychiatric illnesses, he says.

To bring his idea to life, he collaborated with an ophthalmologist, a psychiatrist, and colleagues from his engineering school to develop a screening device. They also created and trained the AI models that analyze retinal images.

Ideas from his thesis led to the creation of the Smart Eye Kiosk, an AI-powered tool that scans the network of small veins that deliver blood to the inner retina. The tool monitors stress levels and mental health. It also screens for basic eye diseases such as diabetic retinopathy, as well as damage to retinal blood vessels caused by high blood sugar.

Retinal images also can reveal physiological changes in the brain associated with psychiatric disorders such as schizophrenia and bipolar disorder, Appaji says. The kiosk uses AI models to analyze measurements of the vasculature network, such as vessel thickness, which can be biomarkers for psychiatric conditions. Since mental illnesses can be linked to genetics, relatives of patients with schizophrenia and bipolar disorder were also invited to participate in a study funded by India’s Cognitive Science Research Initiative’s Department of Science & Technology. The clinical data from this study can pave the way for earlier, more accurate diagnoses.

“The biological basis for this is fascinating,” Appaji says. “The retina is the only place in the human body where the central nervous system and the vascular system can be visualized directly and noninvasively. Anatomically, the retina is an extension of the posterior part of the brain. Therefore, physiological changes in the brain are often reflected in the eyes.”

This kiosk was developed in collaboration with Tan Tock Seng Hospital and Nanyang Technological University, which was funded by Ng Teng Fong Healthcare Innovation Program.

He earned his Ph.D. in 2020 from Maastricht, and he received the Best Thesis Award from the university’s Mental Health and Neuroscience Research Institute. Appaji credits his time at the school for his multidisciplinary approach to developing medical devices.

“Having the perspectives of mentors from diverse fields was essential to help me move my research beyond theory into a data-driven diagnostic tool,” he says.

He was then named institutional coordinator of R&D at B.M.S. and later was promoted to be its head.

An adult Indian man looking at a rectangular device in his hand, labeled u201cdozeeu201d. Abhishek Appaji working on a smart bed sensor that continuously monitors a patient’s vital signs without the use of wires or wearable sensors.Abhishek Appaji

A wireless smart bed to monitor vital signs

Appaji continues to develop technologies for patients who need them most. “I feel a deep need to bridge this gap and ensure innovations have a tangible impact on society,” he says. In addition to the Smart Eye Kiosk, he improved the performance of the sensors of the smart beds that continuously monitor a patient’s vital signs without the use of wires or wearable sensors. The beds help hospital staff check on their patients in a noninvasive way.

The project was done in collaboration with health AI company Dozee (Turtle Shell Technologies) in Bengaluru. The system measures mechanical microvibrations produced by the body in response to the ejection of blood into the aorta, which occurs with each heartbeat. A thin, industrial-grade sensor sheet is placed underneath the mattress. Additional funding is being provided by India’s Department of Science and Technology.

“These sensors are incredibly sensitive,” Appaji says. “They pick up minute mechanical tremors through the mattress material.”

The sensors detect the force of the patient’s heartbeat and the expansion and contraction of their chest during respiration. The vibrations are converted into electrical signals and analyzed using deep learning algorithms developed by Appaji and his team at the university in collaboration with Dozee.

The technology is used in more than 200 hospitals throughout India and in thousands of households, he says.

Mentoring budding entrepreneurs

Appaji is also executive director of the BMSreenivasiah Innovators Guild Foundation, dedicated to nurturing entrepreneurial talent among students and faculty across the BMS group of Institutions. A not-for-profit company promoted by the BMS Education Trust, BIG Foundation provides a structured ecosystem for innovation, incubation, and startup growth.

There, Appaji mentors budding entrepreneurs, offering advice on business plans, product pitches, marketing strategies, and licensing. Participants are students and faculty members.

The foundation has incubated more than 10 ventures, according to Appaji.

“The majority are centered on health care applications,” he says, “and have successfully secured backing from investors and seed funds.”

Taking IEEE’s mission to heart

Appaji was introduced to IEEE as an undergraduate when one of his professors encouraged him to volunteer for a conference sponsored by the IEEE Engineering in Medicine and Biology Society. He transcribed the seminars for session chairs, assisted with managing the talks, and helped answer attendees’ questions.

“That experience was transformative,” he recalls. “I was amazed to find myself in the same room with the speakers and scientists who had authored the very textbooks I was studying.

“It was then that I realized IEEE is far more than just technology and volunteering; it is a global platform for high-level networking with world-class scientists and technologists.”

Appaji has served in several IEEE leadership positions, including 2018–2019 chair of the Young Professionals Bangalore Section. He is now treasurer of the IEEE Education Society, chair of IEEE Computer Society Bangalore Chapter, member of the steering committee of IEEE DataPort, and serves on the IEEE Member and Geographic Activities and IEEE Educational Activities boards.

“What motivates me to remain active within IEEE is the profound alignment between my personal goals and the organizational mission of advancing technology for the benefit of humanity,” he says. “My journey has shown me that IEEE is much more than a professional society; it is a global platform that allows me to collaborate with a diverse network of experts to solve local humanitarian challenges.”

The organization has helped fund some of Appaji’s lifesaving work. During the COVID-19 pandemic, he received a grant from the IEEE Humanitarian Technologies Board and Region 10 to develop 3D-printed protective equipment for people in Bengaluru’s underserved communities. The virus spread quickly in the high-density areas, where social distancing was nearly impossible. The kits, which included a door opener to avoid high-touch surfaces and an elbow-operated soap dispenser, were sent to nearly 500 households.

“This work remains one of my most meaningful contributions to humanitarian technology,” Appaji says, “demonstrating how engineering can be rapidly deployed to protect vulnerable populations during a global crisis.”

He advises younger IEEE members to: “Say yes to taking on roles of responsibility. Don’t wait for a formal title to lead; instead, start by volunteering to do small, manageable tasks within your local chapter or section.”

“The networking opportunities and leadership skills you gain through these early responsibilities will shape your professional career far more than any textbook ever could.”

Researchers Create Biological Robots Featuring Functional Nervous Systems

Researchers Create Biological Robots Featuring Functional Nervous Systems

Engineers have long tried to mimic life. They’ve built machine learning algorithms modeled after the human brain, designed machines that walk like dogs or fly like insects, and taught robots to adapt, however clumsily, to the world around them.

Now they are skipping imitation altogether.

Instead of taking inspiration from biology, they are building robots out of it: fashioning tiny, free-swimming assemblages of living cells that organize into self-directed systems, complete with neurons that wire themselves into functional circuits.

The result, reported last month in Advanced Science, is what the researchers call a “neurobot.”

These living machines could help scientists better understand how simple neural networks give rise to complex behaviors, a foundational step toward building cyborg systems that integrate biological tissue with engineered control. And with further refinement, they could be put to use in applications ranging from precision tissue repair to environmental cleanup.

“My general reaction is, ‘Wow, this is amazing!’ ” says Kate Adamala, a synthetic biologist at the University of Minnesota Twin Cities, who was not involved in the research. “This truly puts the engineering component into bioengineering.”

Toward Internal Control

Neurobots mark the latest advance in a series of increasingly sophisticated biological machines developed by Tufts University biologist Michael Levin and his collaborators.

First described in 2020, these clusters of living cells, when removed from their normal developmental context and cultured in simple saline conditions, spontaneously self-organize in such a manner that they move and act in novel ways. Under the microscope, they look like irregular, translucent blobs of tissue, but their coordinated motion reveals an emergent order that is unlike anything found in the natural world.

“These things don’t occur naturally,” says Carlos Gershenson, a computer scientist at Binghamton University, State University of New York, who studies artificial life and complex systems but was not involved in the neurobot research. “They’re made with natural cells, but we’re the ones arranging them.”

The earliest examples of this technology, called xenobots, were built from frog-derived tissues and mainly from a single type of structural cell. Despite the simplicity of their construction, however, they could propel themselves through water using beating hair-like projections called cilia. They survived for days without added nutrients. And they could repair minor damage, all without any scaffolding materials or genetic manipulation. Some could even self-replicate by spontaneously sweeping up loose stem cells.

Still, for all the novelty of these biological machines, their behavior was essentially mechanical. Their movements were driven by anatomy and physics, not by anything resembling internal control. They could sense chemical cues, change direction accordingly, and even retain traces of past experiences, as detailed in a preprint posted 17 March on bioRxiv.

But many other simple organisms—fungi, protists, and bacteria included—can do much the same. To achieve more flexible, coordinated behavior, they would need a way to integrate information across the body and dynamically direct their actions. Neurobots begin to provide that missing layer of control.

Small tufts of hairlike cilia, combined with the neurobot’s nervous system, allow it to move on its own. Haleh Fotowat

Linking Neural Activity to Action

Like earlier xenobots, neurobots are still built from frog cells, but they are now endowed with neurons that mature from partially differentiated stem cells. These nerve cells develop alongside structural tissues, forming branching connections throughout the autonomous beings. This means they can relay electrochemical signals from cell to cell.

And unlike other laboratory models of the nervous system—brain organoids, say, or lab-on-a-chip technologies—neurobots move. They swim, explore, and respond to their surroundings in ways that tie electrical signaling to observable movement, producing patterns of physical activity distinct from their non-neural counterparts.

Neurobots spend less time idling and more time exploring. They also trace looping and spiraling paths rather than repeating simple trajectories. And they respond differently to neuroactive drugs.

If the organizing principles that enable these internally guided motions and reflexes can now be deciphered, they could then be harnessed to produce more predictable biological functions, says Haleh Fotowat, a neuroengineer from Harvard’s Wyss Institute for Biologically Inspired Engineering, who collaborated with Levin’s team on the study.

“We’re still very early in terms of understanding the system and its capabilities.” But once the scientists understand how the neurobots self-organize, she says, “then we can begin to engineer on top of that.”

Beyond the practical, neurobots also raise deeper epistemological questions about the nature of biological organization, notes Levin. “Where does form and function come from in the first place?” he asks. “When it’s not evolved and it’s not engineered, where do these patterns come from?”

“This is a model system for asking those kinds of questions,” Levin says—in frog and human constructs alike.

From Discovery to Deployment

Among the many variations on the biobot theme are “anthrobots,” built from clusters of human lung cells instead of frog tissue.

Levin’s team now plans to add human neural cells to their anthrobots, extending the neurobot framework into a fully human context. Then, through further conditioning and guided learning, these living machines—like dogs trained to sniff for bombs—may become capable of adapting their behavior in predictable ways.

“The hope would be that you could teach them or train them to do what you want them to do,” says Josh Bongard, a computer scientist and roboticist at the University of Vermont.

Bongard was not involved in the neurobot study but is a frequent collaborator of Levin’s. Together, they cofounded the nonprofit Institute for Computationally Designed Organisms and a commercial startup, Fauna Systems, to advance biobot-related technologies.

According to Fauna CEO Naimish Patel, the company is initially targeting environmental sensing applications, aiming to deploy xenobots in settings such as aquaculture, wastewater monitoring, and pollutant detection, where the technology’s ability to integrate multiple signals could provide an early readout of ecosystem health.

If the xenobots encounter a mixture of stressors—say, elevated heavy metals, shifts in pH, and traces of agricultural runoff—their collective changes in movement or activity could provide a sensitive, real-time signal that something in the environment is amiss.

Precedent for this idea comes from Poland, where many cities already use freshwater mussels as living sentinels of water quality, wired with sensors that register when the animals clamp their shells shut in response to pollutants. Xenobots could extend this concept further, Patel says, potentially offering greater sensitivity and specificity by integrating multiple environmental cues into a single, measurable behavioral response. And neurobots could eventually push this fusion of sensing and computation into ever more sophisticated territory, he adds.

But the technical hurdles remain substantial—and the practical opportunities with simpler, non-neural versions are already compelling—so the first-gen xenobots, for the time being, remain the focus of Fauna’s initial product-development efforts, Patel says. “Right now, we’re looking for the intersection between unmet commercial need and emerging capability.”

The Isotope Revolution: Transforming Cancer Treatment with Radiotherapeutics

The Isotope Revolution: Transforming Cancer Treatment with Radiotherapeutics

In this episode of Denatured, you’ll listen to Dr. Marc Hedrick, President and CEO of Plus Therapeutics and Dr. Phil Kantoff, CEO & Co-founder of Convergent Therapeutics. They discuss breakthroughs like alpha-emitting isotopes, supply chain solutions and why radiotherapeutics is biotech’s next big frontier.

Insights Gained by Exoskeletons from a Tenacious User’s Experience

Insights Gained by Exoskeletons from a Tenacious User’s Experience

It’s easy to assume that Robert Woo was defined by the accident that took away his ability to walk.

Certainly, the day of his accident—14 December 2007—was a turning point. Woo, an architect working on the new Goldman Sachs headquarters in New York City, hadn’t attended his company’s holiday party the night before, and that morning he was the only one in the trailer that served as the construction-site office. He was bent over his laptop when, 30 floors above, a crane’s nylon sling gave way, sending about 6 tonnes of steel plummeting toward the trailer. The roof collapsed, folding Woo in half and smashing his face into his laptop, which smashed through his desk.

“I was conscious throughout the whole ordeal,” Woo remembers. “It was an out-of-body experience. I could hear myself screaming in pain. I could hear the voices of the rescue workers. I heard one firefighter say, ‘Don’t worry, we’re getting to you.’” The rescue workers hauled him out of the rubble and got him to the emergency room in 18 minutes flat; with one lung crushed and the other punctured, he wouldn’t have lasted much longer. In those frantic early moments, a doctor told him that he might be paralyzed from the neck down for the rest of his life. He remembers asking the doctors to let him die.

Woo simply couldn’t imagine how a paralyzed version of himself could continue living his life. Then 39 years old, he worked long hours and jetted around the world to supervise the construction of skyscrapers. More important, he had two young boys, ages 6 months and 2 years. “I couldn’t see having a life while being paralyzed from the neck down, not being able to teach my boys how to play ball,” he recalls. “What kind of life would that be?”

Robert Woo walks inside the Wandercraft facility in New York City using the company’s latest self-balancing exoskeleton. Nicole Millman

But in a Manhattan showroom last May, Woo showed that he’s not defined by that accident, which left him paralyzed from the chest down, but with the use of his arms. Instead, he has defined himself by how he has responded to his injury, and the new life he built after it.

In the showroom, Woo transferred himself from his wheelchair to a 80-kilogram (176-pound) exoskeleton suit. After strapping himself in, he manipulated a joystick in his left hand to rise from a chair and then proceeded to walk across the room on robotic legs. Woo’s steps were short but smooth, and he clanked as he walked.

This exoskeleton, from the French company Wandercraft, is one of the first to let the user walk without arm braces or crutches, which most other models require to stabilize the user’s upper body. The battery-powered exoskeleton took care of both propulsion and balance; Woo just had to steer. The bulky apparatus had a backplate that extended above Woo’s head, a large padded collar, armrests, motorized legs, and footplates. Walking across the room, he appeared to be half man, half machine. On the other side of the showroom’s plate-glass window, on Park Avenue, a kid walking by with his family came to a dead halt on the sidewalk, staring with awe at the cyborg inside.

Person seated wearing a full lower-body robotic exoskeleton for mobility assistance

Close-up of a hand operating the joystick and controls on a powered wheelchair armrestRobert Woo prepares to walk in a Wandercraft exoskeleton; the device’s controller enables him to stand up, initiate walk mode, and choose a direction. Bryan Anselm/Redux

The amazement on the boy’s face was reminiscent of Woo’s young sons’ reaction when they saw a photo of Woo trying out an early exoskeleton, back in 2011. “Their first comment was, ‘Oh, Daddy’s in an Iron Man suit,’” he remembers. Then they asked, “When are you going to start flying?” To which Woo replied, “Well, I’ve got to learn how to walk first.”

The title of exoskeleton superhero suits Woo. He’s as soft-spoken and mild-mannered as Clark Kent, with a smile that lights up his face. Yet the strength underneath is undeniable; he has built a new life out of sheer determination.

For 15 years, he’s been a test pilot, early adopter, and clinical-study subject for the most prominent exoskeletons under development around the world. He placed the first order for an exoskeleton that was approved for home use, and he learned what it was like to be Iron Man around the house. Throughout it all, he has given the companies detailed feedback drawn from both his architectural design skills and his user experience. He has shaped the technology from inside of it.

Saikat Pal, a researcher at the New Jersey Institute of Technology, in Newark, met Woo during clinical trials for Wandercraft’s first model. Like so many others in the field, Pal quickly recognized that Woo brought a lot to the table. “He’s a super-mega user of exoskeletons: very enthusiastic, very athletic,” Pal says. “He’s the perfect subject.”

By pushing the technology forward, Woo has paved the way for thousands of people with spinal cord injuries as well as other forms of paralysis, who are now benefiting from exoskeletons in rehab clinics and in their homes. “Our bionics program at Mount Sinai started with Robert Woo,” says Angela Riccobono, the director of rehabilitation neuropsychology at Mount Sinai Hospital, in New York City, where Woo became an outpatient after his accident. “We have a plaque that dedicates our bionics program to him.”

Robert Woo walks down a sidewalk in New York City in 2015 using a ReWalk exoskeleton, one of the first exoskeletons designed for use outside the rehab clinic. Eliza Strickland

It’s a fitting tribute. Woo’s post-accident life has been marked by victories, frustrations, deep love, and one devastating loss, and yet he has continued to devote himself to bionics. And while his vision for exoskeletons hasn’t changed, experience has reshaped what he expects from them in his lifetime.

Rebuilding a Life After his Spinal Cord Injury

Long before Woo ever stood up in a robotic suit, he had developed the habits of mind that would later make him an unusually perceptive test pilot.

Woo has always been a builder, a tinkerer, a fixer. Growing up in the suburbs of Toronto, he put together model kits of battleships and airplanes without looking at the instructions. “I just put things together the way I thought it would work out,” he says. He trained as an architect and in 2000 joined the Toronto-based firm Adamson Associates Architects, a job that soon had him traveling to Europe and Asia to work on corporate high-rises.

Adamson specializes in taking the stunning designs of visionary architects and turning them into practical buildings with elevators and bathrooms. “Most of the design architects don’t really have a clue about how to build buildings,” Woo says. He liked solving those problems; he liked reconciling beautiful designs with the stubborn reality of construction. That talent for understanding a structure from the inside and spotting the flaws would prove essential later.

After his accident, Woo had two major surgeries to stabilize his crushed spine, which required surgeons to cut through muscles and nerves that connected to his arms. For two months, he couldn’t feel or move his arms; there was a chance he never would again. Only when sensation began creeping back into his fingertips did he allow himself to imagine a different future. If he wasn’t paralyzed from the neck down, he thought, maybe more of his body could be brought back online. “My focus was to walk again,” he says.

Woo was discharged in March 2008 and went back to his New York City apartment. He was still bedridden and required around-the-clock care. He doesn’t much like to talk about this next part: By May, his then-wife had moved back to Canada and filed for divorce, asking for full custody of their two children. Woo remembers her saying, “I can’t look after three babies, and one of them for life.”

It was a dark time. Riccobono of Mount Sinai, who met Woo shortly after he became an outpatient there in 2008, recalls the despondent look on his face the first time they talked. “I wasn’t sure that he wasn’t going to take his life, to be honest,” she says. “He felt like he had nothing to live for.”

One photo shows a smiling man in an exoskeleton with his arm around a smiling woman. The other photo shows a metal plaque saying that the Rehabilitation Bionics Program was made possible by the advocacy and dedication of Robert Woo.Angela Riccobono of Mount Sinai Hospital (left) credits Woo with jump-starting the hospital’s bionics program; a plaque in the department of rehabilitation medicine recognizes his role.

Yet Woo harbors no animosity toward his ex-wife. “If we hadn’t separated and gone through the custody hearing, I don’t think I would have gotten this far,” he says. To win partial custody of his children, Woo had to become independent. He had to get off narcotic pain medications, regain strength, and learn how to navigate life in a wheelchair. He had to show that he no longer needed constant nursing, and that he could take care of both himself and his boys.

There were milestones: learning how to get back into his wheelchair after a fall, learning to drive a car with hand controls, learning to manage his body as it was, not as it had been. The biggest change came when he reconnected with his high school sweetheart, a vivacious woman named Vivian Springer. She was then dividing her time between Toronto and New York City, and she had a son who was almost the same age as Woo’s two boys. Springer had worked in a nursing home and knew how to change the sheets without getting him out of bed; she was currently working in human resources and knew how to deal with insurance companies. “You wouldn’t believe how much stress it lifted off of me,” Woo says. Over time, they became a family.

Man using a robotic exoskeleton with support, shopping and standing with children.Robert Woo’s wife, Vivian, was trained in how to operate the device he used at home. His sons, Tristan (left) and Adrien, grew up watching their dad test exoskeletons. Left: Lifeward; Right: Robert Woo

Once Woo had that foundation in place, Riccobono witnessed a profound change. “He went from focusing on ‘what I can’t do anymore’ to ‘What’s still possible? What can I do with what I have?’” At Mount Sinai, Woo remembers asking his doctor Kristjan Ragnarsson, who was then chairman of the department of rehabilitation medicine, if he would ever walk again. “His response was, ‘Yes, you can walk again,’” Woo remembers, “‘but not the way you used to walk.’”

First Steps in an Exoskeleton

As soon as he had regained use of his hands, Woo had started googling, looking for anything that could get him back on his feet. He tried rehab equipment like the Lokomat, which used a harness suspended above a treadmill to enable users to walk. But at the time, it required three physical therapists: one to move each leg and one to control the machine. It was a far cry from the independent strides he dreamed of.

Several years in, he learned about two companies that had built something radically different: exoskeleton suits for people with spinal cord injuries. These prototypes had motors at the knees and the hips to move the legs, with the user stabilizing their upper body with arm braces. Woo desperately wanted to try one, although the technology was still experimental and far from regulatory approval. So he took the idea to Ragnarsson, asking if Mount Sinai could bring an exoskeleton into its rehab clinic for a test drive. Ragnarsson, who’s now retired, remembers the request well. “He certainly gave us the kick in the behind to get going with the technology,” he says.

Man in robotic exoskeleton walks with canes during rehab demo as clinicians observeRobert Woo tries out an early exoskeleton from Ekso Bionics at Mount Sinai Hospital, where he first began testing the technology. Mario Tama/Getty Images

Ragnarsson had seen decades of failed attempts to get paraplegics upright, including “inflatable garments made of the same material the astronauts used when they went to the moon,” he says. All those devices had proved too tiring for the user; in contrast, the battery-powered exoskeletons promised to do most of the work. And he knew one of the founders of Ekso Bionics, a Berkeley, Calif.–based company that had built exoskeletons for the military. In 2011, Ekso brought its new clinical prototype to Mount Sinai.

The day came for Woo’s first walk. “I was excited, and I was also scared, because I hadn’t stood up for almost five years,” he remembers. “Standing up for the first time was like floating, because I couldn’t feel my feet.” In that first Ekso model, Woo didn’t control when he stepped forward; instead, he shifted his weight in preparation, and then a physical therapist used a remote control to trigger the step. Woo walked slowly across the room, using a walker to stabilize his upper body, his steps a symphony of clunks and creaks and whirs. He found it mentally and physically exhausting, but the effort felt like progress.

Robert Woo stands using an exoskeleton and embraces his wife, Vivian. Woo says that exoskeleton use has both physical and psychological benefits. Mt. Sinai

Riccobono was there for those first steps, with tears running down her face. “I remembered how he looked the day I first met him, so defeated,” she says. “To see him rise from the chair, to see him rise to a standing position, to see how tall he was, to see him take those first steps—it was beautiful.” Ragnarsson saw clear benefits to the technology. “Any type of walking is good physiologically,” he says. “And it’s a tremendous boost psychologically to stand up and look someone in the eye.” Woo remembers hugging his partner, Springer, and for the first time not worrying about running over her toes with his wheelchair. I first met Woo a few days later, during his third session with the Ekso at Mount Sinai.

Two people stand outside; one uses blue exoskeleton crutches for mobility.Ann Spungen (left), a researcher at a Veterans Affairs hospital, led early clinical trials of exoskeletons. Her research focused on the medical benefits of exoskeleton use. Robert Woo

Later that same year, at a Department of Veterans Affairs (VA) hospital in the Bronx, Woo got to try a prototype of the world’s other leading exoskeleton: the ReWalk, from the Israeli company of the same name (since renamed Lifeward). VA researchers, led by Ann Spungen, were keen to determine if exoskeleton use had real medical value for veterans with spinal cord injuries. Woo was part of that clinical trial, for which he had more than 70 walking sessions, and he’s since been in many others. But he remembers the first VA trial with the most gratitude. “Dr. Spungen’s first exoskeleton clinical trial really turned things around for me,” he says.

Over the course of the trial’s nine intense months, Woo says he saw noticeable improvements to many facets of his health. “By the end of the trial, I eliminated about three-quarters of my medication intake,” he says, including narcotic pain pills and medication for muscle spasms. He grew fitter, with less body fat, more muscle mass, and lower cholesterol. His circulation improved, he says, causing scrapes and cuts to heal more quickly, and his digestion improved too. The results Woo experienced have generally been borne out in research studies at the VA and elsewhere—exoskeletons aren’t just good for the mind, they’re good for the body.

Improving Exoskeletons From the Inside

During the VA trial, Woo began to think of exoskeletons not as miraculous machines, but as works in progress.

Man wearing robotic exoskeleton and using crutches on a city sidewalkPierre Asselin (right), a biomedical engineer, worked with Robert Woo during clinical trials of exoskeletons. He says Woo was always pushing the limits of the technology. Robert Woo

Pierre Asselin, the biomedical engineer coordinating the VA’s study, watched participants respond very differently to the equipment. “These devices are not the equivalent of walking—you’re tired after walking a mile,” he says. He notes that later models of both the Ekso and ReWalk enabled users to initiate each step through software that recognized when they shifted their weight. Asselin adds that the cognitive load is “like learning to drive a manual transmission car, where at first you’re really struggling to coordinate the clutch and the brake.” Woo picked it up immediately, he remembers.

Man in a leg exoskeleton reaches into a kitchen cabinet while another observes.Robert Woo uses an exoskeleton to reach items in a kitchen cabinet during a test of the device’s utility for everyday tasks. Eliza Strickland

Woo became an invaluable partner, Asselin says. “When we first started with the devices, there was no training manual. We developed all of that through collaboration with Robert and other participants.” Woo pushed the limits of the technology, Asselin says, whether it was seeing how many steps he could take on one battery charge or simulating a failure mode. “He’d say, ‘What happens if I was to fall? What would be the approach to getting up?’”

Woo approached the ReWalk the way he had approached buildings in his previous life: He looked inside the structure and found the weak points. An early model left some users with leg abrasions where the straps rubbed—a small injury for most people, but a serious risk for someone who can’t feel a wound forming. Woo suggested better padding and stronger abdominal supports to redistribute the load. He also hated the heavy backpack that carried the battery and computer, so one afternoon he grabbed an old pack, cut off the straps, and rebuilt it into a compact hip-mounted pouch. Then he snapped photos and sent them to the company. The next model arrived with a fanny pack.

Hand-drawn concept sketch of a modular device labeled u201cReWack 6.0u201d with notes and arrowsRobert Woo sent detailed design sketches as part of his feedback to exoskeleton engineers. Robert Woo

Sometimes his fixes were more ambitious. One Ekso unit that he used at Mount Sinai kept shutting down after 30 minutes. Woo felt the hip motors and found them hot to the touch. “I said, ‘Can I remove these? I’m going to make a really quick fix, okay? Give me a drill and I’ll put a couple of holes in it,” he recalls telling the therapists, proposing to create a DIY heat sink. He wasn’t allowed to modify the prototype, but a year later the company introduced improved cooling around the hip motors. “There is a Robert Woo design on this device,” one therapist told him.

Eythor Bender, who was then the CEO of Ekso, called Woo to thank him for his feedback and invite him to spend a week at Ekso’s headquarters. “There was no lack of engineering power in that building,” says Bender. “But sometimes when you work with engineers, they overlook important things.” Bender says Woo brought both design skills and lived experience to his weeklong residency. “He told the engineers, ‘Guys, this has to be something that people actually like to wear.’”

Patient in exoskeleton uses walker, flanked by doctor in lab coat and man in suitEkso Bionics CEO Eythor Bender and Mount Sinai physician Kristjan Ragnarsson were both on hand for Woo’s early trials of the Ekso device. Ragnarsson says he saw physical and psychological benefits of exoskeleton use. Robert Woo

The longer Woo tested, the further ahead he started thinking. With motors only at the hips and knees, every exoskeleton still required crutches. Add powered ankles, he told the Ekso and ReWalk teams, and the suits could balance themselves, freeing the user’s hands. But Woo was ahead of his time. “They said they weren’t going to do that. They weren’t going to change their whole platform,” he remembers. Years later, though, hands-free exoskeletons like those from Wandercraft would emerge built around exactly that principle.

When the Exoskeleton Came Home

By the mid-2010s, Woo had pushed the technology as far as he could in clinics. What he wanted now was to use an exoskeleton at home.

That milestone came after ReWalk’s exoskeleton became the first to win FDA approval for home use in 2014. ReWalk engineers still remember Woo’s help on the final tests for that personal-use model. It was the end of May in 2015, recalls David Hexner, the company’s vice president of research and development. “He said, ‘Guys, this is great. I’m going to buy it.’”

Woo was the first customer to buy an exoskeleton to bring home, paying US $80,000 out of pocket. His insurance wouldn’t cover the cost, but he was able to make the purchase in part because of a legal settlement after his accident. The home-use model came with a requirement that the user have at least one companion who was fully trained in operating the device. In Woo’s case, that meant that Springer learned to suit him up, realign his balance, and help him if he fell.

On delivery day, two SUVs drove up to a hotel down the street from Woo’s condo in the Toronto area. The technicians hauled two huge boxes into a hotel room and assembled his personal exoskeleton. They took Woo’s measurements, made adjustments, checked the software. This latest version could be controlled by either weight shifting or tapping commands on a smartwatch, and Woo had the app ready. He tested out everything in the hotel room, signed off, and then the technicians drove his robot legs to his home.

That was the start of his golden period with the ReWalk—similar to the excitement many people experience with a new piece of exercise equipment. “I used it every day for a few hours, and then I started logging how many steps I’d done,” Woo says. “My last count was probably just slightly over a million steps,” he says, with half of those steps taken in his home unit and half in training programs and clinical trials.

Person using a ReWalk exoskeleton with crutches beside stacked ReWalk shipping boxes The ReWalk was the first exoskeleton available for use outside the clinic. Robert Woo’s ReWalk arrived in two large boxes. ReWalk engineers assembled it in a hotel room, and Woo tried it out in the hallway before taking it home. Robert Woo

Tristan, Woo’s eldest son, remembers doing laps with his dad in the condo’s underground parking garage while his dad was training for a 5-kilometer race in New York City. Tristan admits that he had previously been embarrassed about his dad, but training for the race shifted something for him. “I was so used to not wanting to tell people that my dad was in a wheelchair, but then I shared his passion for the training,” he says. “When people would come up to us, I’d tell them about it.”

The ReWalk could turn ordinary moments into small engineering projects. On weekends, Woo would take his boys to the golf course behind their condo and bring a baseball. He had rigged two holsters to the sides of the suit so he could stash a crutch and stand on three points (two legs and one arm) while he pitched or caught. Throw, switch crutches, catch. On the day of his accident, he never thought such a scene would be possible. But with the exoskeleton, it became just another design problem to solve. “It’s a little more work. It’s not perfect,” he says. “But in the end, you still get to do what you want to do—which is play ball with your sons.”

Tristan, now a college student, says he didn’t realize at the time how hard his dad worked to make those mundane activities possible. “Reflecting on it now,” he says, “he has shaped almost every element of my life, and he definitely is my hero.”

But even during that golden stretch, the ReWalk had a way of asserting its limits. Every so often it would freeze mid-stride and require a reboot—a small technical hiccup in theory, but a serious problem when there’s a person strapped inside. Once, when he was walking on his own in the parking garage (without his mandated companion), the suit glitched and went into “graceful collapse” mode, lowering him to a seated position on the ground. Woo had to ask security to bring his wheelchair and a dolly.

He had imagined the exoskeleton would be most useful in the kitchen. Woo loves to cook, and he had pictured himself standing at the stove, looking down into pots, and moving easily between counter and sink. The reality, he found out, was more complicated. “It’s actually very time-consuming and troublesome” to cook in an exoskeleton, he says.

Preparing a meal meant first rolling through the kitchen in his wheelchair to gather every ingredient and utensil, then transferring himself into the ReWalk and moving himself into position at the counter, stopping at just the right moment. “That’s when I fell once,” Woo says. “I collided with the counter and then lost my balance and fell backward.” If all went well, he’d lean either on one crutch or the counter to keep his balance while he worked. But if he’d forgotten to grab the vinegar from the cabinet, he’d have to go into walk mode, crutch over to it, and figure out how to carry the bottle back to his workstation.

Powered exoskeleton suit and crutches positioned in a modern clinical room Sitting unused in Robert Woo’s home, his ReWalk exoskeleton reflects both the promise and the limits of early devices. Robert Woo

Gradually, he stopped trying. The suit, which he’d once worn every day, spent more time sitting idle in the hallway; like so many abandoned treadmills and stationary bikes, it gathered dust. Part of the reason was the exoskeleton’s practical limitations, but part of it was a shocking development: In 2024, Vivian was diagnosed with an aggressive form of breast cancer. She died in November of that year, at the age of 54.

Woo was scheduled to begin a new round of clinical trials for the Wandercraft home-use exoskeleton that month. In the aftermath of Vivian’s death, he postponed his sessions and questioned whether he would ever go back. “At the time, I thought, ‘What’s the point?’” he remembers.

He did go back, though. “He just rolled up, right into my office,” says Mount Sinai’s Riccobono. “He still had Vivian’s box of ashes on his lap. That’s how fresh it was.” Woo brought the box into a meeting of spinal cord injury patients and shared the story of losing the love of his life. And he told them that he heard his wife’s voice in his head every day, telling him to get back to work. Once again, he was figuring out how to move forward with what he had.

How Close Are We to Everyday Exoskeletons?

In the Wandercraft showroom last May, Woo steered toward the door to the street, technicians flanking him like spotters. The slope down to the sidewalk was barely an inch high, but everyone tensed. He shifted his weight and took a step forward. The suit halted automatically. He tried again—step, stop; step, stop—as the suit kept detecting the slight decline and a safety feature kicked in. The Wandercraft isn’t yet rated for slopes of more than 2 percent, and even the gentle pitch of Park Avenue was enough to trigger its safeguards. When he finally reached the sidewalk, Woo broke into a grin. A man in the back seat of a stopped Uber leaned out his window, filming.

Knee brace with straps and a leg showing a fresh, red incision scar.During testing of the Wandercraft exoskeleton, straps caused an abrasion on Robert Woo’s leg, which he documented as part of his feedback to the company. Robert Woo

Woo had recently completed seven sessions with the Wandercraft at the VA hospital and had been impressed overall. But at the showroom, he rolled up his pants leg to reveal an abrasion on his shin, the result of a strap that had worn away a patch of skin during a long walking session. He would later send Wandercraft a nine-page assessment with photos and a technology wish list, asking the company to work on things like padding, variable walking speeds, and deeper squats.

Wandercraft’s engineers relish that kind of user feedback, says CEO Matthieu Masselin. Exoskeletons are a far more difficult engineering problem than humanoid robots, he explains. “You basically have two systems of equal importance. You know about the robot—it’s fully quantified and measured. But you don’t know what the person is doing, and how the person is moving within the device.”

Since Woo began testing exoskeletons 15 years ago, both the technology and the market have made strides. ReWalk and Ekso won FDA clearance for clinical use in the 2010s, and both now sell home-use versions. The companies have sold thousands of exoskeletons to rehab clinics and personal users, and they see room for growth; in the United States alone, about 300,000 people live with spinal cord injuries, and millions more have mobility impairments from stroke, multiple sclerosis, or other conditions. The VA began supplying devices to eligible veterans in 2015, and Medicare recently established a system for reimbursement, a move that private insurers are beginning to follow. What was once experimental is slowly becoming established.

Researchers who test the devices say the technology still has significant limits. Pal, of the New Jersey Institute of Technology, mentions battery life, dexterity, and reliability as ongoing challenges. But, he says with a laugh, “Our bodies have evolved over many millions of years—these machines will need a bit more time.” Pal hopes the companies will keep pushing the technological frontier. “My lifetime goal is to see the day when someone like Robert Woo can wake up in the morning, put this device on, and then live an ordinary life.”

For Woo, the real question about the self-balancing Wandercraft was: Could he cook with it? In the VA hospital’s home mockup, he tried it out in the kitchen, stepping sideways to retrieve items from cabinets and squatting to grab something from the fridge’s lower shelf. For the first time in years, he could work at a counter without leaning on crutches. “The self-standing exoskeleton changes everything,” he says. He imagines a user placing a Thanksgiving turkey on a tray attached to the suit and walking it into the dining room.

Back in the showroom, Woo finishes the demo and brings the suit to a seated position before transferring back to his wheelchair. After so many years of testing prototypes, he’s now realistic about the technology’s timeline. A truly all-day exoskeleton—the kind you live in, the kind that replaces a wheelchair—may be a decade or more away. “It may not be for me,” he says. But that’s no longer the point. He’s thinking about young people who are newly injured, who are lying in hospital beds and trying to imagine how their lives can continue. “This will give them hope.”